List of Contents

Infectious Disease Diagnostics Market Size, Share, and Trends 2024 to 2034

Infectious Disease Diagnostics Market (By Product: Assays & Reagents, Instruments, Software; By Disease Type: Hepatitis, Human Immunodeficiency Virus, Influenza, Others; By Technology: Immunodiagnostics, Clinical Microbiology, Polymerase Chain Reaction, Next-generation Sequencing, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2034

  • Last Updated : July 2024
  • Report Code : 3100
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Infectious Disease Diagnostics Market 

5.1. COVID-19 Landscape: Infectious Disease Diagnostics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Infectious Disease Diagnostics Market, By Product

8.1. Infectious Disease Diagnostics Market, by Product, 2024-2034

8.1.1 Assays & Reagents

8.1.1.1. Market Revenue and Forecast (2021-2034)

8.1.2. Instruments

8.1.2.1. Market Revenue and Forecast (2021-2034)

8.1.3. Software

8.1.3.1. Market Revenue and Forecast (2021-2034)

Chapter 9. Global Infectious Disease Diagnostics Market, By Disease Type

9.1. Infectious Disease Diagnostics Market, by Disease Type, 2024-2034

9.1.1. Hepatitis

9.1.1.1. Market Revenue and Forecast (2021-2034)

9.1.2. Human Immunodeficiency Virus

9.1.2.1. Market Revenue and Forecast (2021-2034)

9.1.3. Influenza

9.1.3.1. Market Revenue and Forecast (2021-2034)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2021-2034)

Chapter 10. Global Infectious Disease Diagnostics Market, By Technology 

10.1. Infectious Disease Diagnostics Market, by Technology, 2024-2034

10.1.1. Immunodiagnostics

10.1.1.1. Market Revenue and Forecast (2021-2034)

10.1.2. Clinical Microbiology

10.1.2.1. Market Revenue and Forecast (2021-2034)

10.1.3. Polymerase Chain Reaction

10.1.3.1. Market Revenue and Forecast (2021-2034)

10.1.4. Next-generation Sequencing

10.1.4.1. Market Revenue and Forecast (2021-2034)

10.1.5. Others

10.1.5.1. Market Revenue and Forecast (2021-2034)

Chapter 11. Global Infectious Disease Diagnostics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Product (2021-2034)

11.1.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.1.3. Market Revenue and Forecast, by Technology (2021-2034)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.1.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.1.4.3. Market Revenue and Forecast, by Technology (2021-2034)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.1.5.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.1.5.3. Market Revenue and Forecast, by Technology (2021-2034)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.2.3. Market Revenue and Forecast, by Technology (2021-2034)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.2.4.3. Market Revenue and Forecast, by Technology (2021-2034)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.5.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.2.5.3. Market Revenue and Forecast, by Technology (2021-2034)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.6.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.2.6.3. Market Revenue and Forecast, by Technology (2021-2034)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Product (2021-2034)

11.2.7.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.2.7.3. Market Revenue and Forecast, by Technology (2021-2034)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.3.3. Market Revenue and Forecast, by Technology (2021-2034)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.3.4.3. Market Revenue and Forecast, by Technology (2021-2034)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.5.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.3.5.3. Market Revenue and Forecast, by Technology (2021-2034)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.6.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.3.6.3. Market Revenue and Forecast, by Technology (2021-2034)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Product (2021-2034)

11.3.7.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.3.7.3. Market Revenue and Forecast, by Technology (2021-2034)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.4.3. Market Revenue and Forecast, by Technology (2021-2034)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.4.4.3. Market Revenue and Forecast, by Technology (2021-2034)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.5.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.4.5.3. Market Revenue and Forecast, by Technology (2021-2034)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.6.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.4.6.3. Market Revenue and Forecast, by Technology (2021-2034)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Product (2021-2034)

11.4.7.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.4.7.3. Market Revenue and Forecast, by Technology (2021-2034)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.5.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.5.3. Market Revenue and Forecast, by Technology (2021-2034)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Product (2021-2034)

11.5.4.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.5.4.3. Market Revenue and Forecast, by Technology (2021-2034)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Product (2021-2034)

11.5.5.2. Market Revenue and Forecast, by Disease Type (2021-2034)

11.5.5.3. Market Revenue and Forecast, by Technology (2021-2034)

Chapter 12. Company Profiles

12.1. Abbott Laboratories

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Becton Dickinson and Company

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. bioMerieus SA

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Bio-Rad Laboratories

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Danaher Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. F Hoffman-La Roche

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Hologic Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Luminex Corporation

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Qiagen Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Thermo Fisher Scientific Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client